Gain Therapeutics, Inc. (GANX) vs PDS Biotechnology Corporation (PDSB)
A side-by-side comparison of Gain Therapeutics, Inc. and PDS Biotechnology Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GANX
Gain Therapeutics, Inc.
$1.70HealthcareDelayed quote: Oct 6, 2026, 12:45 PM EDT
PDSB
PDS Biotechnology Corporation
$1.07HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
Total return — GANX vs PDSB
growth of $100 · dividends reinvested · last 6yGANX -84.9% (-27.0%/yr)PDSB -77.2% (-21.9%/yr)PDSB compounded faster over this window
GANX PDSB
GANX vs PDSB: by the numbers
- •GANX is the larger company ($72M vs $60M market cap).
Metrics side by side
Valuation
| Metric | GANX | PDSB |
|---|---|---|
| P/B ratio | 6.40 | N/A |
Profitability
| Metric | GANX | PDSB |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -178.06% | N/A |
| ROIC | -159.24% | -3699.99% |
Growth (annualized)
| Metric | GANX | PDSB |
|---|---|---|
| Total return CAGR (5Y) | -25.06% | -39.13% |
Frequently asked
- How have GANX and PDSB total returns compared?
- Over the past 5 years, GANX delivered -25.06% and PDSB delivered -39.13% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.